Physician
Pinelake Regional Hospital LLC
Pinelake Regional Hospital LLC was paid $43.34M by Medicaid between Jan 2018 and Dec 2024, across 284 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoPINELAKE REGIONAL HOSPITAL LLC
MAYFIELD, KY 42066
MAYFIELD, KY 42066
33aNPI1891892741assigned 09/20/2006
33bProvider typePediatrics Physician
28Total paid$43.34M
24GClaims916,998
24DCodes billed284
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Kentucky
Rank by total paid#1 of 156
Median peer was paid$41K
This provider vs. median1,052×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 139,360 | $8.73M | |
| 2019 | 144,887 | $7.33M | |
| 2020 | 129,901 | $5.18M | |
| 2021 | 136,071 | $5.45M | |
| 2022 | 129,761 | $5.40M | |
| 2023 | 129,778 | $6.03M | |
| 2024incomplete | 107,240 | $5.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 24,738 | 19,980 | $5.80M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 33,816 | 27,681 | $4.61M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 8,248 | 5,595 | $3.01M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 6.0% | 3,885 | 2,936 | $2.60M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.9% | 2,777 | 2,291 | $2.14M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 3.9% | 4,978 | 4,597 | $1.71M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 5,583 | 4,075 | $1.47M |
| G0378 | Hospital observation service, per hour | 3.3% | 2,773 | 2,023 | $1.44M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.9% | 3,490 | 2,486 | $1.27M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 10,860 | 9,707 | $1.15M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 21,235 | 5,405 | $888K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.9% | 9,473 | 6,908 | $819K |
272 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 5,833 | $714K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.3% | 17,588 | $580K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 17,329 | $558K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 4,924 | $527K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.2% | 4,746 | $502K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 18,036 | $474K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.1% | 1,033 | $460K |
| 36415 | Collection of venous blood by venipuncture | <1% | 122,889 | $424K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,271 | $408K |
| 80053 | Comprehensive metabolic panel | <1% | 48,799 | $399K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,229 | $370K |
| 73630 | <1% | 6,027 | $360K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 48,766 | $353K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,667 | $333K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 6,093 | $299K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 845 | $291K |
| 59025 | Fetal non-stress test | <1% | 3,723 | $268K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 7,460 | $265K |
| 73030 | <1% | 3,704 | $258K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,965 | $256K |
| 73562 | <1% | 3,529 | $240K | |
| 73610 | <1% | 3,270 | $236K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 745 | $233K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,913 | $223K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,381 | $216K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,567 | $212K |
| 73130 | <1% | 2,886 | $193K | |
| 73110 | <1% | 2,325 | $183K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,022 | $181K |
| 72131 | <1% | 626 | $179K | |
| 97597 | <1% | 2,592 | $172K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,519 | $170K |
| 76770 | <1% | 2,000 | $162K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 11,016 | $162K |
| 72110 | <1% | 2,101 | $153K | |
| 87486 | <1% | 5,947 | $149K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 5,025 | $146K |
| 87581 | <1% | 4,967 | $144K | |
| 71250 | <1% | 594 | $137K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,800 | $130K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 498 | $130K |
| 95886 | <1% | 1,925 | $122K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,971 | $121K |
| 80061 | Lipid panel | <1% | 10,950 | $114K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,155 | $113K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,556 | $111K |
| 72050 | <1% | 1,054 | $104K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,541 | $103K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 218 | $97K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,950 | $94K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,157 | $94K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 901 | $93K |
| 97162 | <1% | 1,748 | $90K | |
| 74018 | <1% | 2,124 | $88K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,565 | $85K |
| 83735 | <1% | 15,439 | $80K | |
| 82805 | <1% | 1,735 | $76K | |
| 81025 | <1% | 7,188 | $71K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,999 | $68K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,093 | $64K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,218 | $63K |
| 84484 | <1% | 6,185 | $63K | |
| 97161 | <1% | 1,166 | $61K | |
| 80081 | <1% | 996 | $61K | |
| 83880 | <1% | 2,511 | $60K | |
| 81003 | <1% | 12,472 | $58K | |
| 81001 | <1% | 10,401 | $57K | |
| 96376 | <1% | 1,106 | $53K | |
| 82607 | <1% | 4,281 | $51K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,262 | $45K |
| 73564 | <1% | 550 | $44K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 173 | $44K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,642 | $42K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 848 | $41K |
| 73080 | <1% | 514 | $41K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,877 | $40K |
| 87040 | <1% | 2,546 | $39K | |
| 73502 | <1% | 2,387 | $38K | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,833 | $38K |
| 83690 | <1% | 6,407 | $37K | |
| 84439 | <1% | 4,950 | $36K | |
| 93971 | <1% | 332 | $35K | |
| 87186 | <1% | 3,917 | $35K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,922 | $35K |
| 95911 | <1% | 381 | $35K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,957 | $35K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 97 | $35K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 86 | $34K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,159 | $33K |
| 84481 | <1% | 2,413 | $32K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,121 | $32K |
| 82150 | <1% | 5,649 | $32K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 130 | $32K |
| 82962 | <1% | 5,224 | $30K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,164 | $30K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 181 | $30K |
| 87077 | <1% | 5,862 | $29K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,894 | $29K |
| 70486 | <1% | 80 | $29K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,307 | $28K |
| 76536 | <1% | 213 | $28K | |
| 85610 | <1% | 5,898 | $27K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,693 | $26K |
| 83605 | <1% | 2,859 | $26K | |
| 92526 | <1% | 783 | $26K | |
| 93017 | <1% | 222 | $25K | |
| 84145 | <1% | 1,444 | $25K | |
| 86850 | <1% | 1,928 | $23K | |
| 72114 | <1% | 393 | $22K | |
| 85730 | <1% | 3,366 | $22K | |
| 86696 | <1% | 1,402 | $22K | |
| 86003 | <1% | 197 | $21K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 335 | $20K |
| 73560 | <1% | 371 | $19K | |
| 87070 | <1% | 2,915 | $19K | |
| 97035 | <1% | 747 | $19K | |
| 73590 | <1% | 258 | $19K | |
| 74022 | <1% | 274 | $19K | |
| 12001 | <1% | 97 | $18K | |
| 85379 | <1% | 2,155 | $18K | |
| 87205 | <1% | 2,005 | $17K | |
| 86694 | <1% | 1,301 | $17K | |
| 87088 | <1% | 2,694 | $17K | |
| 82565 | <1% | 1,605 | $17K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 5,642 | $17K |
| 84703 | <1% | 2,080 | $17K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,096 | $17K |
| 29125 | <1% | 162 | $17K | |
| 87081 | <1% | 2,402 | $16K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,589 | $16K |
| 80074 | <1% | 410 | $16K | |
| 87507 | <1% | 59 | $16K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 724 | $16K |
| 84702 | <1% | 1,156 | $15K | |
| 72100 | <1% | 242 | $15K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,584 | $14K |
| 82728 | <1% | 1,425 | $14K | |
| 73090 | <1% | 191 | $14K | |
| 86140 | <1% | 3,127 | $14K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,141 | $13K |
| 36600 | <1% | 1,792 | $13K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 380 | $13K |
| 73140 | <1% | 200 | $13K | |
| 87634 | <1% | 204 | $12K | |
| 90715 | <1% | 565 | $12K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,279 | $12K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 572 | $11K |
| 83540 | <1% | 1,970 | $11K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 616 | $11K |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 970 | $10K |
| 84403 | <1% | 500 | $10K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,265 | $9K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,612 | $9K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,440 | $9K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,299 | $9K |
| 76830 | Ultrasound, transvaginal | <1% | 57 | $9K |
| 83550 | <1% | 1,177 | $8K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,219 | $8K |
| 80055 | <1% | 138 | $8K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 28 | $7K |
| 82550 | <1% | 1,500 | $7K | |
| 78227 | <1% | 12 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,577 | $7K |
| 86900 | <1% | 2,522 | $6K | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,510 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,950 | $6K |
| 71101 | <1% | 155 | $6K | |
| 92523 | <1% | 36 | $6K | |
| 86039 | <1% | 607 | $6K | |
| 85652 | <1% | 1,834 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 152 | $6K |
| 83970 | <1% | 165 | $6K | |
| 72070 | <1% | 56 | $5K | |
| 86901 | <1% | 2,158 | $5K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 35 | $5K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,441 | $5K |
| 84550 | <1% | 1,218 | $5K | |
| 95909 | <1% | 101 | $5K | |
| 82950 | <1% | 1,071 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,390 | $4K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 426 | $4K |
| 76642 | <1% | 45 | $4K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 21 | $4K |
| 87807 | <1% | 265 | $4K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 235 | $3K |
| 72040 | <1% | 41 | $3K | |
| 76870 | <1% | 14 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 33 | $3K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,350 | $3K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 161 | $3K |
| 82627 | <1% | 144 | $3K | |
| 95910 | <1% | 31 | $3K | |
| 84436 | <1% | 121 | $3K | |
| 84146 | <1% | 147 | $2K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 61 | $2K |
| 82746 | <1% | 184 | $2K | |
| 84402 | <1% | 111 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 194 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,765 | $2K |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 224 | $2K |
| 82105 | <1% | 133 | $2K | |
| 84156 | <1% | 696 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 345 | $2K |
| 82570 | <1% | 493 | $2K | |
| 87899 | <1% | 64 | $2K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 93 | $2K |
| 82652 | <1% | 50 | $2K | |
| 73060 | <1% | 17 | $1K | |
| 84100 | <1% | 322 | $1K | |
| J3490 | Unclassified drugs | <1% | 620 | $1K |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 191 | $1K |
| 87506 | <1% | 14 | $1K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 13 | $1K |
| 83525 | <1% | 143 | $1K | |
| 83001 | <1% | 81 | $1K | |
| 87075 | <1% | 150 | $1K | |
| 92587 | <1% | 21 | $1K | |
| 80164 | <1% | 128 | $1K | |
| 80069 | <1% | 107 | $1K | |
| 86695 | <1% | 101 | $1K | |
| 97012 | <1% | 28 | $966.94 | |
| 82670 | <1% | 47 | $964.81 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 32 | $946.11 |
| 93270 | <1% | 77 | $925.83 | |
| 74019 | <1% | 18 | $848.10 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 184 | $824.86 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 116 | $751.40 |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 12 | $712.92 |
| 82140 | <1% | 58 | $693.46 | |
| 83630 | <1% | 33 | $678.67 | |
| 86592 | <1% | 187 | $675.50 | |
| 87522 | Neg quan hep c or qual rna | <1% | 13 | $634.94 |
| 82553 | <1% | 72 | $624.50 | |
| 86376 | <1% | 56 | $591.79 | |
| 71271 | <1% | 33 | $581.69 | |
| 86431 | <1% | 110 | $479.84 | |
| 82010 | <1% | 75 | $424.22 | |
| 83655 | <1% | 39 | $415.77 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 144 | $413.93 |
| J3230 | Injection, chlorpromazine hcl, up to 50 mg | <1% | 29 | $387.32 |
| 87045 | <1% | 33 | $383.34 | |
| 82947 | <1% | 110 | $364.83 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 305 | $343.44 |
| 84681 | <1% | 13 | $330.32 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 204 | $288.99 |
| 82043 | <1% | 64 | $277.22 | |
| 87210 | <1% | 56 | $269.36 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 269 | $254.66 |
| 84482 | <1% | 18 | $231.36 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 89 | $231.01 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 40 | $229.49 |
| 83789 | <1% | 18 | $222.03 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 15 | $205.29 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 16 | $188.17 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 15 | $186.74 |
| 86800 | <1% | 14 | $180.90 | |
| 83002 | <1% | 12 | $149.45 | |
| 82575 | <1% | 36 | $136.35 | |
| 87177 | <1% | 14 | $134.87 | |
| 86787 | <1% | 13 | $130.04 | |
| 80076 | <1% | 13 | $112.99 | |
| 84630 | <1% | 15 | $100.08 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 21 | $94.92 |
| 85018 | <1% | 46 | $86.53 | |
| 86308 | <1% | 17 | $74.14 | |
| 82044 | <1% | 12 | $70.41 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 61 | $60.94 |
| J3410 | Injection, hydroxyzine hcl, up to 25 mg | <1% | 13 | $55.21 |
| 85014 | <1% | 27 | $54.26 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 129 | $41.25 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 14 | $36.12 |
| A9270 | Non-covered item or service | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.